Literature DB >> 2963969

Quinolinate neurotoxicity in cortical cell culture.

J P Kim1, D W Choi.   

Abstract

The central neurotoxicity of the endogenous tryptophan metabolite, quinolinate, has been postulated to participate in the pathogenesis of the neuronal cell loss associated with several neurological disease states. In the present study, quinolinate neurotoxicity was quantitatively studied in dissociated cell cultures prepared from the fetal mouse neocortex. Sufficient exposure of cortical cultures to quinolinate was associated with considerable neuronal cell loss, but no glial cell loss; this neurotoxicity could be blocked by 2-amino-5-phosphonovalerate and kynurenate, drugs known to block N-methyl-D-aspartate receptors. The quinolinate dose-toxicity relationship showed that the potency of quinolinate as a neurotoxin is relatively low, especially with brief (20 min) exposure times, where an ED50 of 2 mM was observed. However, with longer exposure times of 24 and 96 h, quinolinate is more potent: the latter exposure was characterized by an ED50 of 250-400 microM. Ion substitution experiments suggested that quinolinate neurotoxicity can be separated into two distinct components on the basis of differences in time course and ionic dependence: an acute, sodium-dependent "excitotoxic" component, marked by early cell swelling; and a late, calcium-dependent component, marked by delayed cell degeneration. Acute neuronal swelling was seen only with exposure to quinolinate concentrations in excess of 1 mM, so under actual pathophysiological conditions, quinolinate neurotoxicity might be nearly completely related to the calcium-dependent component, with little or no "excitotoxic" contribution.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963969     DOI: 10.1016/0306-4522(87)90066-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  22 in total

1.  Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome.

Authors:  W F Owen; J Petersen; D M Sheff; R D Folkerth; R J Anderson; J M Corson; A L Sheffer; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Sleep disturbance and kynurenine metabolism in depression.

Authors:  Hyong Jin Cho; Jonathan Savitz; Robert Dantzer; T Kent Teague; Wayne C Drevets; Michael R Irwin
Journal:  J Psychosom Res       Date:  2017-05-22       Impact factor: 3.006

Review 3.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

4.  Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid.

Authors:  J F Reinhard
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

Review 5.  Inflammation and depression: is there a causal connection with dementia?

Authors:  B E Leonard; A Myint
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

6.  Regulation of dopamine function in the nucleus accumbens of the rat by the thalamic paraventricular nucleus and adjacent midline nuclei.

Authors:  M W Jones; I C Kilpatrick; O T Phillipson
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

Review 7.  The role of the kynurenine metabolism in major depression.

Authors:  Aye-Mu Myint; Markus J Schwarz; Norbert Müller
Journal:  J Neural Transm (Vienna)       Date:  2011-12-03       Impact factor: 3.575

8.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 9.  Tryptophan, adenosine, neurodegeneration and neuroprotection.

Authors:  T W Stone; C M Forrest; G M Mackay; N Stoy; L G Darlington
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

10.  Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention.

Authors:  Robert D Oades; Aye-Mu Myint; Maria R Dauvermann; Benno G Schimmelmann; Markus J Schwarz
Journal:  Behav Brain Funct       Date:  2010-06-09       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.